Farxiga (Dapagliflozin) Cost in Virginia: 2026 Pricing, Insurance, and Savings Guide

What Does Farxiga Actually Cost in Virginia in 2026?

The manufacturer list price for Farxiga (dapagliflozin 10 mg, 30 tablets) set by AstraZeneca is approximately $620 per month, and that figure holds across Virginia retail pharmacies in 2026. Without insurance or a discount program, you will pay close to that full amount at CVS, Walgreens, or independent pharmacies statewide.

That $620 number deserves context. Farxiga remains under patent protection with no FDA-approved generic dapagliflozin on the U.S. market as of May 2026. The FDA-approved prescribing information for Farxiga lists three distinct indications: improvement of glycemic control in type 2 diabetes, reduction of hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF), and reduction of sustained eGFR decline and cardiovascular death in adults with chronic kidney disease [1]. Each of these indications may trigger different insurance coverage pathways. A Virginia patient prescribed Farxiga for CKD, for example, may face a different prior authorization process than someone prescribed it for type 2 diabetes, even within the same plan.

Cash-pay prices vary modestly by pharmacy. Discount platforms like GoodRx and RxSaver show Virginia prices ranging from $500 to $580 at major chain pharmacies, depending on location. Independent pharmacies in rural parts of the state sometimes price slightly higher due to lower purchasing volume.

Virginia Medicaid Coverage for Farxiga

Virginia Medicaid does cover Farxiga, but requires prior authorization (PA) before dispensing. This means your prescribing clinician must submit clinical documentation showing that the medication is medically necessary for your specific diagnosis.

The PA process in Virginia typically requires documentation of the patient's diagnosis (type 2 diabetes, HFrEF, or CKD), prior medication trials, and relevant lab values such as HbA1c or eGFR. For type 2 diabetes, Virginia Medicaid formulary guidelines generally require evidence that metformin was tried first or is contraindicated. The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors as preferred second-line therapy in patients with established atherosclerotic cardiovascular disease, heart failure, or CKD, regardless of HbA1c [2]. Citing this guideline in your PA request strengthens the case.

For heart failure and CKD indications, the evidence base is particularly strong. The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo (HR 0.74, 95% CI 0.65 to 0.85, P<0.001) over a median follow-up of 18.2 months [3]. Dr. John McMurray, lead investigator of DAPA-HF, stated: "Dapagliflozin reduced the risk of worsening heart failure and death from cardiovascular causes, whether or not diabetes was present" [3]. This trial was a turning point. Virginia Medicaid PA reviewers are generally familiar with this evidence, and approval rates for heart failure indications tend to be higher than for glycemic control alone.

Processing times for Virginia Medicaid PA typically range from 24 to 72 hours for standard requests. Urgent requests can be expedited within 24 hours if the prescriber indicates clinical urgency.

How the AstraZeneca Savings Card Works in Virginia

AstraZeneca offers a manufacturer savings card for commercially insured patients that can reduce out-of-pocket Farxiga costs to as little as $0 per month. This program is available to Virginia residents who carry commercial (private) insurance.

The savings card covers the difference between your insurance copay and a set maximum benefit. Eligible patients can save up to $150 per 30-day prescription fill, with an annual maximum that AstraZeneca adjusts periodically. There are specific exclusions. Patients enrolled in any federal healthcare program (Medicare Part D, Medicaid, TRICARE, VA benefits) are ineligible for the savings card [1]. This is a federal anti-kickback statute requirement, not an AstraZeneca policy choice.

For Virginia patients on Medicare Part D, the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective January 2025) provides an alternative ceiling on Farxiga spending. Under this provision, once your total out-of-pocket Part D spending reaches $2,000 in a calendar year, you pay $0 for covered drugs for the remainder of that year [4]. If Farxiga is on your Part D formulary and you hit the cap by mid-year, the second half of the year costs nothing. That math matters: six months of Farxiga copays at a typical Part D tier 3 rate of $47 per month totals $282, well under the cap. But if Farxiga sits on a specialty tier with 25% to 33% coinsurance, you could reach the $2,000 ceiling within three to four fills.

Is Compounded Dapagliflozin Legal in Virginia?

Yes. Compounded dapagliflozin is legal in Virginia when prepared by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Virginia Board of Pharmacy regulations permit 503A compounding consistent with federal law under section 503A of the Federal Food, Drug, and Cosmetic Act [5].

A 503A pharmacy compounds medications on an individual prescription basis. The prescriber writes for dapagliflozin specifying the dose and form, and the compounding pharmacist prepares it using bulk pharmaceutical-grade dapagliflozin powder. The FDA's guidance on compounding requires that the compounded product is not essentially a copy of a commercially available drug, but pharmacies may compound when they document a clinical difference (different strength, different dosage form, or an allergy-related formulation change) [5].

Cost is the obvious draw. Compounded dapagliflozin from Virginia 503A pharmacies can cost substantially less than brand Farxiga. Some patients report paying under $100 per month. The tradeoff: compounded products do not undergo FDA approval for safety, efficacy, or manufacturing consistency. They lack the bioequivalence data that an FDA-approved generic would carry. The Endocrine Society's 2023 position statement on compounded medications notes that "compounded preparations should be used only when an FDA-approved alternative does not meet the clinical needs of the patient" [6]. Virginia clinicians should document the clinical rationale when prescribing compounded dapagliflozin.

Which Virginia Insurance Plans Cover Farxiga?

Most major commercial insurers operating in Virginia include Farxiga on their formularies, though tier placement and cost-sharing vary. Anthem Blue Cross Blue Shield, Aetna, Cigna, UnitedHealthcare, and Optima Health all list Farxiga, typically on tier 3 (preferred brand) or tier 4 (non-preferred brand) depending on the plan year and specific product.

Prior authorization requirements are common across commercial plans, not just Medicaid. Anthem's Virginia formulary, for example, requires PA for Farxiga and specifies step therapy through metformin for the type 2 diabetes indication. For heart failure and CKD, some plans waive the step-therapy requirement given the strength of the DAPA-HF and DAPA-CKD evidence [3][7].

The DAPA-CKD trial (N=4,304) showed that dapagliflozin reduced the composite of sustained decline in eGFR of 50% or greater, end-stage kidney disease, or death from renal or cardiovascular causes by 39% (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) [7]. Dr. Hiddo Heerspink, principal investigator, noted: "The benefits were consistent regardless of the presence or absence of type 2 diabetes" [7]. This finding expanded Farxiga's clinical relevance well beyond diabetes management and has shifted many formulary committees toward more favorable coverage.

Virginia state employee health plans (administered through the Department of Human Resource Management) cover Farxiga under their prescription drug benefit. The 2026 plan year places it on the preferred brand tier with a $50 copay after deductible for the COVA Care plan.

For patients with Virginia marketplace (ACA) plans, Farxiga coverage depends on the specific metal tier and insurance carrier. Silver and Gold plans generally include it with prior authorization. Bronze plans may impose higher coinsurance, sometimes 30% to 40% after deductible, which on a $620 list price yields $186 to $248 per fill before reaching out-of-pocket maximums.

Telehealth Prescribing of Farxiga in Virginia

Virginia law permits telehealth prescribing of Farxiga. The Virginia Board of Medicine allows clinicians to establish a patient-provider relationship via synchronous audio-video telehealth and prescribe non-controlled medications, which includes SGLT2 inhibitors like dapagliflozin [8].

This is straightforward. A Virginia-licensed physician, nurse practitioner, or physician assistant can evaluate you via video visit, review your labs, confirm an appropriate indication, and electronically prescribe Farxiga to a Virginia pharmacy. No in-person visit is required for the initial prescription under current Virginia telehealth regulations, provided the telehealth encounter meets the standard of care.

Several telehealth platforms serve Virginia patients seeking SGLT2 inhibitor prescriptions. Lab monitoring is required: baseline and periodic assessment of renal function (eGFR, serum creatinine), potassium, and volume status. Most telehealth prescribers will require you to obtain labs at a local draw station (Quest, Labcorp, or hospital lab) before or shortly after initiating therapy. The FDA label recommends assessing renal function prior to initiation and periodically thereafter [1].

Farxiga carries specific safety considerations that telehealth prescribers must address. These include risk of diabetic ketoacidosis (including euglycemic DKA), genital mycotic infections, urinary tract infections, and volume depletion, particularly in patients on loop diuretics or those over age 65 [1]. A thorough telehealth intake should screen for these risks.

How to Get the Lowest Farxiga Price in Virginia

Start with your insurance formulary. If Farxiga is covered, apply the AstraZeneca savings card on top of your commercial copay. That combination typically yields the lowest net cost for commercially insured patients.

If you are uninsured, compare these options in order:

1. AstraZeneca patient assistance program (AZ&Me): Provides free Farxiga to qualifying uninsured patients with household income at or below 400% of the federal poverty level [9]. Apply through the AstraZeneca website or by calling their support line.

2. Compounded dapagliflozin from a Virginia 503A pharmacy: Legal, lower cost, but lacks FDA bioequivalence data. Appropriate when a clinical justification exists.

3. Discount card platforms: GoodRx, RxSaver, and SingleCare can reduce cash prices to the $500 to $580 range at Virginia pharmacies. Not a dramatic savings over list price, but every reduction counts on a $620 monthly medication.

4. Pharmacy shopping: Costco and Sam's Club pharmacies in Virginia often price below CVS and Walgreens for cash-pay prescriptions. You do not need a warehouse membership to use the pharmacy in most cases.

For Medicare Part D enrollees, the $2,000 out-of-pocket cap means annual Farxiga spending is capped regardless of plan tier placement [4]. If Farxiga is the most expensive drug you take, you may reach that cap within the first half of the year and pay nothing for the remainder.

Clinical Value: Why Farxiga Costs What It Does

Farxiga's pricing reflects a drug with three major FDA indications supported by large-scale randomized controlled trials. The cardiovascular and renal outcomes data are not incremental. They are substantial.

In DAPA-HF, the number needed to treat (NNT) to prevent one primary outcome event was 21 over 18.2 months [3]. For context, that NNT is comparable to or better than many established cardiovascular therapies. The DECLARE-TIMI 58 trial (N=17,160) showed that dapagliflozin reduced hospitalization for heart failure by 27% (HR 0.73, 95% CI 0.61 to 0.88) in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors [10].

SGLT2 inhibitors as a class have earned a Class I recommendation (strongest level) from the American Heart Association / American College of Cardiology 2022 Heart Failure Guidelines for patients with HFrEF, regardless of diabetes status [11]. This guideline-level endorsement drives formulary inclusion and supports PA approvals across Virginia insurance plans.

The cost-effectiveness literature is also relevant. A 2021 analysis published in the Annals of Internal Medicine estimated that dapagliflozin for CKD had an incremental cost-effectiveness ratio of approximately $86,600 per quality-adjusted life year (QALY) gained compared to standard care [12]. At conventional willingness-to-pay thresholds of $100,000 to $150,000 per QALY, Farxiga meets cost-effectiveness benchmarks for the CKD indication.